Drug targeting to decrease cardiotoxicity – determination of the cytotoxic effect of GnRH-based conjugates containing doxorubicin, daunorubicin and methotrexate on human cardiomyocytes and endothelial cells

Scholarly Works

• Ibrahim, A. A.; Nsairat, H.; Al-Sulaibi, M.; El-Tanani, M.; Jaber, A. M.; Lafi, Z.; Barakat, R.; Abuarqoub, D. A.; Mahmoud, I. S.; Obare, S. O.; Aljabali, A. A. A.; Alkilany, A. M.; Alshaer, W. Doxorubicin conjugates: a practical approach for its cardiotoxicity alleviation. Expert opinion on drug delivery 2024, 21, 399–422. doi:10.1080/17425247.2024.2343882
• Szász, Z.; Enyedi, K. N.; Takács, A.; Fekete, N.; Mező, G.; Kőhidai, L.; Lajkó, E. Characterisation of the cell and molecular biological effect of peptide-based daunorubicin conjugates developed for targeting pancreatic adenocarcinoma (PANC-1) cell line. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2024, 173, 116293. doi:10.1016/j.biopha.2024.116293
• Moiseeva, A. A.; Artyushin, O. I.; Anikina, L. V.; Globa, A. A.; Klemenkova, Z. S.; Andreev, M. V.; Radchenko, E. V.; Palyulin, V. A.; Brel, V. K. Design of anthracyclines with extremely high cytotoxic properties. Research Square Platform LLC 2024. doi:10.21203/rs.3.rs-3942818/v1
• Mező, G.; Gomena, J.; Ranđelović, I.; Dókus, E. L.; Kiss, K.; Pethő, L.; Schuster, S.; Vári, B.; Vári-Mező, D.; Lajkó, E.; Polgár, L.; Kőhidai, L.; Tóvári, J.; Szabó, I. Oxime-Linked Peptide-Daunomycin Conjugates as Good Tools for Selection of Suitable Homing Devices in Targeted Tumor Therapy: An Overview. International journal of molecular sciences 2024, 25, 1864. doi:10.3390/ijms25031864
• Kuloğlu, N.; Karabulut, D.; Kaymak, E.; Akin, A. T.; Ceylan, T.; Yıldırım, A. B.; Yakan, B. Effect of vitamin B12 on methotrexate-induced cardiotoxicity in rats. Iranian journal of basic medical sciences 2024, 27, 733–739.
• Feng, J.; Wu, Y. Endothelial-to-Mesenchymal Transition: Potential Target of Doxorubicin-Induced Cardiotoxicity. American journal of cardiovascular drugs : drugs, devices, and other interventions 2023, 23, 231–246. doi:10.1007/s40256-023-00573-w
• Balogh, B.; Ivánczi, M.; Nizami, B.; Beke-Somfai, T.; Mándity, I. M. ConjuPepDB: a database of peptide-drug conjugates. Nucleic acids research 2020, 49, D1102–D1112. doi:10.1093/nar/gkaa950
• Kurmi, B. D.; Paliwal, R.; Paliwal, S. R. Dual cancer targeting using estrogen functionalized chitosan nanoparticles loaded with doxorubicin-estrone conjugate: A quality by design approach. International journal of biological macromolecules 2020, 164, 2881–2894. doi:10.1016/j.ijbiomac.2020.08.172
• Takasuna, K.; Kazusa, K.; Hayakawa, T. Comprehensive Cardiac Safety Assessment using hiPS-cardiomyocytes (Consortium for Safety Assessment using Human iPS Cells: CSAHi). Current pharmaceutical biotechnology 2020, 21, 829–841. doi:10.2174/1389201020666191024172425
• Piorecka, K.; Smith, D. R. R.; Kurjata, J.; Stanczyk, M.; Stanczyk, W. A. Synthetic routes to nanoconjugates of anthracyclines. Bioorganic chemistry 2020, 96, 103617. doi:10.1016/j.bioorg.2020.103617
• Sun, X.; Liu, J.; Wang, Y.; Bai, X.; Chen, Y.; Qian, J.; Zhu, H.; Liu, F.; Qiu, X.; Sun, S.; Ji, N.; Liu, Y. Methotrexate-cytarabine-dexamethasone combination chemotherapy with or without rituximab in patients with primary central nervous system lymphoma. Oncotarget 2017, 8, 49156–49164. doi:10.18632/oncotarget.17101

Explore citations to this article at